SMO ClinPlus Co. Ltd. (301257) - Total Assets
Based on the latest financial reports, SMO ClinPlus Co. Ltd. (301257) holds total assets worth CN¥1.52 Billion CNY (≈ $223.14 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of SMO ClinPlus Co. Ltd. to assess the company's total reinvestment commitment from operating cash flow.
SMO ClinPlus Co. Ltd. - Total Assets Trend (2019–2025)
This chart illustrates how SMO ClinPlus Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. Check how high is SMO ClinPlus Co. Ltd.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
SMO ClinPlus Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
SMO ClinPlus Co. Ltd.'s total assets of CN¥1.52 Billion consist of 85.6% current assets and 14.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 30.3% |
| Accounts Receivable | CN¥169.47 Million | 11.0% |
| Inventory | CN¥0.00 | 0.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.87 Million | 0.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how SMO ClinPlus Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 301257 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SMO ClinPlus Co. Ltd.'s current assets represent 85.6% of total assets in 2025, a decrease from 92.3% in 2019.
- Cash Position: Cash and equivalents constituted 30.3% of total assets in 2025, down from 44.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 11.0% of total assets.
SMO ClinPlus Co. Ltd. Competitors by Total Assets
Key competitors of SMO ClinPlus Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
SMO ClinPlus Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.99 | 5.86 | 2.38 |
| Quick Ratio | 4.99 | 5.86 | 2.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥967.84 Million | CN¥1.14 Billion | CN¥214.61 Million |
SMO ClinPlus Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between SMO ClinPlus Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | CN¥1.54 Billion |
| Market Capitalization | $466.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values SMO ClinPlus Co. Ltd.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SMO ClinPlus Co. Ltd.'s assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SMO ClinPlus Co. Ltd. (2019–2025)
The table below shows the annual total assets of SMO ClinPlus Co. Ltd. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.54 Billion ≈ $225.92 Million |
+7.99% |
| 2024-12-31 | CN¥1.43 Billion ≈ $209.20 Million |
+4.59% |
| 2023-12-31 | CN¥1.37 Billion ≈ $200.01 Million |
+17.76% |
| 2022-12-31 | CN¥1.16 Billion ≈ $169.85 Million |
+187.13% |
| 2021-12-31 | CN¥404.25 Million ≈ $59.15 Million |
+38.26% |
| 2020-12-31 | CN¥292.39 Million ≈ $42.79 Million |
+44.80% |
| 2019-12-31 | CN¥201.93 Million ≈ $29.55 Million |
-- |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.